Oxford Biodyn Share News (OBD)

Oxford BioDynamics raises GBP540,000 in further equity raise

(Alliance News) - Oxford BioDynamics PLC on Friday said it raised GBP543,577 after completing its PrimaryBid offer announced on Tuesday.

IN BRIEF: Oxford BioDynamics raises GBP5.6 million through placing

Oxford BioDynamics PLC - Oxford-based biotechnology firm focused on discovering and developing epigenetic biomarkers - Raises GBP5.6 million via accelerated bookbuild process and through direct subscription. 48.1 million shares are issued pursuant to the placing at an issue price of 11.0 pence per share. Subscribers have conditionally subscribed for 2.5 million shares at issue price. The placing shares and subscription shares represents around 25% of the company's issued share capital. Shore Capital and Baden Hill acted as joint brokers and bookrunners in connection with the placing. Oxford BioDynamics have applied for shares to be admitted to trading on AIM, and expect this trading to commence on August 21.

Oxford BioDynamics proposes GBP7 million fundraise for EpiSwitch plans

(Alliance News) - Oxford BioDynamics PLC on Tuesday said it plans to raise GBP7 million via a placing, subscription and retail offer of new shares in the company.

AIM WINNERS & LOSERS: Empire Metals surges on Pitfield results

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Oxford BioDynamics half-year loss widens; outlook remains uncertain

(Alliance News) - Oxford BioDynamics PLC said on Tuesday that the company will need to generate increased revenue or find additional funding in the remainder of the year, as its half-year loss widened.

Oxford Biodynamics first-half losses widen

(Sharecast News) - Oxford BioDynamics reported revenue of £0.22m in its first half on Tuesday, up from £0.09m in the same period a year earlier.

UK earnings, trading statements calendar - next 7 days

TRADING UPDATES: Trident Royalties takes interest in Mexican project

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

TRADING UPDATES: Knights Group buys St James Law and Baines Wilson

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

IN BRIEF: Oxford BioDynamics reports record orders for blood test

Oxford BioDynamics PLC - Oxford-based biotechnology firm focused on discovery and development of epigenetic biomarkers - Plans acceleration of final development and launch of PSE clinical test in both the UK and US, for availability in the fourth quarter. Commences certification of clinical testing facility within existing Oxford base. Reports the EpiSwitch CiRT blood test continues to gain traction in the US, posting record monthly orders in November and December 2022, and January and March 2023. Adds uptake of the test is growing, through both new and repeat orders. Intends to present both tests in a key note address at the 13th World Clinical Biomarker & Companion Diagnostics Europe Summit.

UK shareholder meetings calendar - next 7 days

Oxford BioDynamics PSE test shows 94% accuracy in cancer screening

(Alliance News) - Oxford BioDynamics PLC on Monday said its EpiSwitch blood test has demonstrated significant potential as a fast and accurate prostate cancer screening diagnostic.

Oxford BioDynamics operating loss widens; EpiSwitch shows promise

(Alliance News) - Oxford BioDynamics PLC on Tuesday said its operating loss widened and revenue remained insubstantial in the financial year that ended September 30, but it said its EpiSwitch product has received a positive response.

AIM WINNERS & LOSERS: Norman Broadbent fourth quarter fee income jumps

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

UK earnings, trading statements calendar - next 7 days